NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE
Identifieur interne : 000011 ( PascalFrancis/Checkpoint ); précédent : 000010; suivant : 000012NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE
Auteurs : C. H. Carriere [Canada] ; N. H. Kang [Canada] ; L. P. Niles [Canada]Source :
- Neuroscience [ 0306-4522 ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Rotenone, which is used as a pesticide and insecticide, has been shown to cause systemic inhibition of mitochondrial complex I activity, with consequent degeneration of dopaminergic neurons within the substantia nigra and striatum, as observed in Parkinson's disease. A novel intrastriatal rotenone model of Parkinson's disease was used to examine the neuroprotective effects of valproic acid (VPA), which is known to upregulate neurotrophic factors and other protective proteins in the brain. Sham or lesioned rats were treated with either vehicle or VPA at a dose of 4 mg/mL in drinking water. The right striatum was lesioned by infusion of rotenone at three sites (2 μg/site) along its rostrocaudal axis. A forelimb asymmetry (cylinder) test indicated a significant (p < 0.01) decrease in use of the contralateral forelimb in rotenone-lesioned animals, in the third week post-lesioning, which was abolished by VPA treatment. Similarly, a significant (p < 0.01) and persistent increase in use of the ipsilateral forelimb in lesioned animals over the 4 weeks of testing, was not seen in animals treated with VPA. Results of the asymmetry test illustrate that intrastriatal infusion of rotenone causes contralateral motor dysfunction, which is blocked by VPA. The significant increase in ipsilateral forelimb use has not been documented previously, and presumably represents a compensatory response in lesioned animals. Six weeks post-surgery, animals were sacrificed by transcardial perfusion. Subsequent immunohistochemical examination revealed a decrease in tyrosine hydroxylase immunoreactivity within the striatum and substantia nigra of rotenone-lesioned animals. VPA treatment attenuated the decrease in tyrosine hydroxylase in the striatum and abolished it in the substantia nigra. Stereological cell counting indicated a significant (p < 0.05) decrease in tyrosine hydroxylase-positive dopamine neurons in the substantia nigra of rotenone-lesioned animals, which was confirmed by Nissl staining. Importantly, this loss of dopamine neurons in rotenone-lesioned animals, was blocked by chronic VPA treatment. These findings strongly support the therapeutic potential of VPA in Parkinson's disease.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:14-0151154Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE</title><author><name sortKey="Carriere, C H" sort="Carriere, C H" uniqKey="Carriere C" first="C. H." last="Carriere">C. H. Carriere</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Kang, N H" sort="Kang, N H" uniqKey="Kang N" first="N. H." last="Kang">N. H. Kang</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Niles, L P" sort="Niles, L P" uniqKey="Niles L" first="L. P." last="Niles">L. P. Niles</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0151154</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0151154 INIST</idno><idno type="RBID">Pascal:14-0151154</idno><idno type="wicri:Area/PascalFrancis/Corpus">000023</idno><idno type="wicri:Area/PascalFrancis/Curation">000B95</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000011</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000011</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE</title><author><name sortKey="Carriere, C H" sort="Carriere, C H" uniqKey="Carriere C" first="C. H." last="Carriere">C. H. Carriere</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Kang, N H" sort="Kang, N H" uniqKey="Kang N" first="N. H." last="Kang">N. H. Kang</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Niles, L P" sort="Niles, L P" uniqKey="Niles L" first="L. P." last="Niles">L. P. Niles</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hamilton, ON L8S 4L8</wicri:noRegion><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Neuroscience</title><title level="j" type="abbreviated">Neuroscience</title><idno type="ISSN">0306-4522</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neuroscience</title><title level="j" type="abbreviated">Neuroscience</title><idno type="ISSN">0306-4522</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Models</term><term>Neuroprotection</term><term>Parkinson disease</term><term>Rotenone</term><term>Valproic acid</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Neuroprotection</term><term>Acide valproïque</term><term>Modèle</term><term>Maladie de Parkinson</term><term>Roténone</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rotenone, which is used as a pesticide and insecticide, has been shown to cause systemic inhibition of mitochondrial complex I activity, with consequent degeneration of dopaminergic neurons within the substantia nigra and striatum, as observed in Parkinson's disease. A novel intrastriatal rotenone model of Parkinson's disease was used to examine the neuroprotective effects of valproic acid (VPA), which is known to upregulate neurotrophic factors and other protective proteins in the brain. Sham or lesioned rats were treated with either vehicle or VPA at a dose of 4 mg/mL in drinking water. The right striatum was lesioned by infusion of rotenone at three sites (2 μg/site) along its rostrocaudal axis. A forelimb asymmetry (cylinder) test indicated a significant (p < 0.01) decrease in use of the contralateral forelimb in rotenone-lesioned animals, in the third week post-lesioning, which was abolished by VPA treatment. Similarly, a significant (p < 0.01) and persistent increase in use of the ipsilateral forelimb in lesioned animals over the 4 weeks of testing, was not seen in animals treated with VPA. Results of the asymmetry test illustrate that intrastriatal infusion of rotenone causes contralateral motor dysfunction, which is blocked by VPA. The significant increase in ipsilateral forelimb use has not been documented previously, and presumably represents a compensatory response in lesioned animals. Six weeks post-surgery, animals were sacrificed by transcardial perfusion. Subsequent immunohistochemical examination revealed a decrease in tyrosine hydroxylase immunoreactivity within the striatum and substantia nigra of rotenone-lesioned animals. VPA treatment attenuated the decrease in tyrosine hydroxylase in the striatum and abolished it in the substantia nigra. Stereological cell counting indicated a significant (p < 0.05) decrease in tyrosine hydroxylase-positive dopamine neurons in the substantia nigra of rotenone-lesioned animals, which was confirmed by Nissl staining. Importantly, this loss of dopamine neurons in rotenone-lesioned animals, was blocked by chronic VPA treatment. These findings strongly support the therapeutic potential of VPA in Parkinson's disease.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0306-4522</s0></fA01><fA02 i1="01"><s0>NRSCDN</s0></fA02><fA03 i2="1"><s0>Neuroscience</s0></fA03><fA05><s2>267</s2></fA05><fA08 i1="01" i2="1" l="ENG"><s1>NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE</s1></fA08><fA11 i1="01" i2="1"><s1>CARRIERE (C. H.)</s1></fA11><fA11 i1="02" i2="1"><s1>KANG (N. H.)</s1></fA11><fA11 i1="03" i2="1"><s1>NILES (L. P.)</s1></fA11><fA14 i1="01"><s1>Department of Psychiatry and Behavioural Neurosciences, Faculty of Health Sciences, McMaster University, 1280 Main Street West</s1><s2>Hamilton, ON L8S 4L8</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA20><s1>114-121</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>17194</s2><s5>354000502701570110</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.1/4</s0></fA45><fA47 i1="01" i2="1"><s0>14-0151154</s0></fA47><fA60><s1>P</s1><s3>PR</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Neuroscience</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Rotenone, which is used as a pesticide and insecticide, has been shown to cause systemic inhibition of mitochondrial complex I activity, with consequent degeneration of dopaminergic neurons within the substantia nigra and striatum, as observed in Parkinson's disease. A novel intrastriatal rotenone model of Parkinson's disease was used to examine the neuroprotective effects of valproic acid (VPA), which is known to upregulate neurotrophic factors and other protective proteins in the brain. Sham or lesioned rats were treated with either vehicle or VPA at a dose of 4 mg/mL in drinking water. The right striatum was lesioned by infusion of rotenone at three sites (2 μg/site) along its rostrocaudal axis. A forelimb asymmetry (cylinder) test indicated a significant (p < 0.01) decrease in use of the contralateral forelimb in rotenone-lesioned animals, in the third week post-lesioning, which was abolished by VPA treatment. Similarly, a significant (p < 0.01) and persistent increase in use of the ipsilateral forelimb in lesioned animals over the 4 weeks of testing, was not seen in animals treated with VPA. Results of the asymmetry test illustrate that intrastriatal infusion of rotenone causes contralateral motor dysfunction, which is blocked by VPA. The significant increase in ipsilateral forelimb use has not been documented previously, and presumably represents a compensatory response in lesioned animals. Six weeks post-surgery, animals were sacrificed by transcardial perfusion. Subsequent immunohistochemical examination revealed a decrease in tyrosine hydroxylase immunoreactivity within the striatum and substantia nigra of rotenone-lesioned animals. VPA treatment attenuated the decrease in tyrosine hydroxylase in the striatum and abolished it in the substantia nigra. Stereological cell counting indicated a significant (p < 0.05) decrease in tyrosine hydroxylase-positive dopamine neurons in the substantia nigra of rotenone-lesioned animals, which was confirmed by Nissl staining. Importantly, this loss of dopamine neurons in rotenone-lesioned animals, was blocked by chronic VPA treatment. These findings strongly support the therapeutic potential of VPA in Parkinson's disease.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17G</s0></fC02><fC02 i1="02" i2="X"><s0>002B02B06</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Neuroprotection</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Neuroprotection</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Neuroprotección</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Acide valproïque</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Valproic acid</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Acido valproico</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Modèle</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Models</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Modelo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Roténone</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Rotenone</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Anticonvulsivant</s0><s5>20</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Anticonvulsant</s0><s5>20</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Anticonvulsivante</s0><s5>20</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>21</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>21</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>21</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>22</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>22</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>22</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>23</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>23</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>23</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>24</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>24</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>24</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>25</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>25</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>25</s5></fC07><fN21><s1>188</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Carriere, C H" sort="Carriere, C H" uniqKey="Carriere C" first="C. H." last="Carriere">C. H. Carriere</name></region><name sortKey="Kang, N H" sort="Kang, N H" uniqKey="Kang N" first="N. H." last="Kang">N. H. Kang</name><name sortKey="Niles, L P" sort="Niles, L P" uniqKey="Niles L" first="L. P." last="Niles">L. P. Niles</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000011 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000011 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:14-0151154
|texte= NEUROPROTECTION BY VALPROIC ACID IN AN INTRASTRIATAL ROTENONE MODEL OF PARKINSON'S DISEASE
}}
| This area was generated with Dilib version V0.6.29. |  |